{"id":"tiotropium-bromide-inhalation-powder-handihaler","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Dry mouth"},{"rate":"1-3%","effect":"Tremor"},{"rate":"2-4%","effect":"Headache"},{"rate":"2-3%","effect":"Pharyngitis"},{"rate":"1-2%","effect":"Urinary retention"}]},"_chembl":{"chemblId":"CHEMBL3545181","moleculeType":"Small molecule","molecularWeight":"490.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tiotropium binds to muscarinic M3 receptors on airway smooth muscle cells, preventing acetylcholine-induced bronchoconstriction. This results in sustained airway relaxation and improved airflow. The drug is formulated as an inhalation powder for direct delivery to the lungs, providing once-daily, 24-hour bronchodilatory effect in chronic obstructive pulmonary disease (COPD) and asthma.","oneSentence":"Tiotropium is a long-acting anticholinergic (antimuscarinic) agent that blocks muscarinic M3 receptors on airway smooth muscle to produce sustained bronchodilation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:48.535Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"},{"name":"Asthma maintenance treatment"}]},"trialDetails":[{"nctId":"NCT05506865","phase":"PHASE4","title":"Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure","status":"COMPLETED","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2012-09","conditions":"COPD","enrollment":73},{"nctId":"NCT02175342","phase":"PHASE2","title":"Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":202},{"nctId":"NCT05165485","phase":"PHASE4","title":"Phase 4 COPD and Suboptimal Inspiratory Flow Rate","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2022-01-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":404},{"nctId":"NCT06487416","phase":"PHASE1","title":"A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-06-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":186},{"nctId":"NCT06326671","phase":"PHASE1","title":"A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-02-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":39},{"nctId":"NCT05986591","phase":"PHASE3","title":"Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Xiromed LLC","startDate":"2022-08-17","conditions":"COPD","enrollment":335},{"nctId":"NCT00239447","phase":"PHASE3","title":"Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-11-26","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":131},{"nctId":"NCT02242266","phase":"PHASE2","title":"Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-07-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":121},{"nctId":"NCT00668772","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder in COPD","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":207},{"nctId":"NCT03964207","phase":"PHASE4","title":"A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":72},{"nctId":"NCT00662740","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":220},{"nctId":"NCT05838703","phase":"PHASE2","title":"Tiotropium Handihaler vs. Tiotropium Respimat in COPD","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2023-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":""},{"nctId":"NCT05161156","phase":"PHASE3","title":"Bioequivalence Study of Tiotropium Bromide Inhalation Powder","status":"COMPLETED","sponsor":"Phargentis SA","startDate":"2022-03-24","conditions":"COPD","enrollment":306},{"nctId":"NCT05246046","phase":"PHASE1","title":"Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2022-02-16","conditions":"Healthy Volunteers","enrollment":88},{"nctId":"NCT00662792","phase":"PHASE3","title":"Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":147},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT03137992","phase":"PHASE3","title":"Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness","status":"COMPLETED","sponsor":"Lupin, Inc.","startDate":"2017-11-21","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":377},{"nctId":"NCT02541006","phase":"PHASE4","title":"Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2014-11","conditions":"COPD","enrollment":58},{"nctId":"NCT02988869","phase":"PHASE4","title":"Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2016-08","conditions":"COPD","enrollment":84},{"nctId":"NCT03395002","phase":"PHASE4","title":"Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2018-03-22","conditions":"COPD","enrollment":58},{"nctId":"NCT04147572","phase":"NA","title":"Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2019-11-01","conditions":"Healthy Volunteer, COPD","enrollment":200},{"nctId":"NCT02566031","phase":"PHASE4","title":"A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-23","conditions":"COPD","enrollment":379},{"nctId":"NCT02059434","phase":"PHASE1","title":"Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-09-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Asthma","enrollment":55},{"nctId":"NCT02603393","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-11-20","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1053},{"nctId":"NCT02796677","phase":"PHASE3","title":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-07-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1595},{"nctId":"NCT02573155","phase":"PHASE1","title":"Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10","conditions":"Asthma (Part 1), COPD (Part 2)","enrollment":134},{"nctId":"NCT01662986","phase":"PHASE4","title":"Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-08-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":79},{"nctId":"NCT01663987","phase":"PHASE4","title":"Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-08-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":79},{"nctId":"NCT02172430","phase":"PHASE3","title":"Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":161},{"nctId":"NCT01937390","phase":"","title":"Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-11-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":645},{"nctId":"NCT00565266","phase":"PHASE3","title":"Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2008-05","conditions":"Asthma","enrollment":210},{"nctId":"NCT02257385","phase":"PHASE3","title":"Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":967},{"nctId":"NCT01395888","phase":"PHASE3","title":"A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":260},{"nctId":"NCT02207829","phase":"PHASE3","title":"A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1017},{"nctId":"NCT01627327","phase":"PHASE3","title":"Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":623},{"nctId":"NCT01124422","phase":"PHASE4","title":"Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":255},{"nctId":"NCT01085045","phase":"PHASE2","title":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2010-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":118},{"nctId":"NCT02331940","phase":"NA","title":"Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients","status":"COMPLETED","sponsor":"University of Crete","startDate":"2010-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":200},{"nctId":"NCT01854645","phase":"PHASE3","title":"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":2103},{"nctId":"NCT01970878","phase":"PHASE3","title":"Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":892},{"nctId":"NCT01462929","phase":"PHASE3","title":"Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":414},{"nctId":"NCT00868231","phase":"PHASE2","title":"Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":30},{"nctId":"NCT00784550","phase":"PHASE4","title":"A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":342},{"nctId":"NCT01587079","phase":"PHASE2","title":"Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2012-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":159},{"nctId":"NCT02473237","phase":"PHASE4","title":"Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)","status":"COMPLETED","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2013-04","conditions":"COPD","enrollment":40},{"nctId":"NCT01922271","phase":"PHASE4","title":"Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":152},{"nctId":"NCT01437748","phase":"PHASE4","title":"Closing Volume Interpretation and Bronchodilators Effect","status":"COMPLETED","sponsor":"University of Milan","startDate":"2011-08","conditions":"Healthy, COPD","enrollment":40},{"nctId":"NCT02254174","phase":"PHASE1","title":"Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-03","conditions":"Healthy","enrollment":36},{"nctId":"NCT02242253","phase":"PHASE2","title":"Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":97},{"nctId":"NCT02172326","phase":"PHASE3","title":"Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":29},{"nctId":"NCT01574651","phase":"PHASE3","title":"The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":934},{"nctId":"NCT01222533","phase":"PHASE2","title":"Tiotropium Respimat Pharmacokinetic Study in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":154},{"nctId":"NCT01072396","phase":"PHASE4","title":"Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":126},{"nctId":"NCT01120691","phase":"PHASE3","title":"Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":2224},{"nctId":"NCT00845728","phase":"PHASE3","title":"Exacerbation Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3439},{"nctId":"NCT00620516","phase":"","title":"Tiotropium 18ug Inhalation Capsule Using a Handihaler® Among Korean COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3008},{"nctId":"NCT00281567","phase":"PHASE3","title":"Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76},{"nctId":"NCT01202188","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":2144},{"nctId":"NCT01119937","phase":"PHASE3","title":"Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":211},{"nctId":"NCT00929110","phase":"PHASE3","title":"1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1066},{"nctId":"NCT00578968","phase":"PHASE4","title":"Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-10","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":36},{"nctId":"NCT00877383","phase":"PHASE3","title":"Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-04","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1142},{"nctId":"NCT00900731","phase":"PHASE3","title":"A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1598},{"nctId":"NCT00846586","phase":"PHASE3","title":"Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1134},{"nctId":"NCT00463567","phase":"PHASE2, PHASE3","title":"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":"Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive","enrollment":2059},{"nctId":"NCT00615459","phase":"PHASE3","title":"A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":169},{"nctId":"NCT01112241","phase":"PHASE4","title":"Bronchodilator Responsiveness in Obliterative Bronchiolitis","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"2010-04","conditions":"Obliterative Bronchiolitis","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"tiotropium bromide inhalation powder HandiHaler","genericName":"tiotropium bromide inhalation powder HandiHaler","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tiotropium is a long-acting anticholinergic (antimuscarinic) agent that blocks muscarinic M3 receptors on airway smooth muscle to produce sustained bronchodilation. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}